AU2018315034A1 - Pharmaceutical compositions - Google Patents
Pharmaceutical compositions Download PDFInfo
- Publication number
- AU2018315034A1 AU2018315034A1 AU2018315034A AU2018315034A AU2018315034A1 AU 2018315034 A1 AU2018315034 A1 AU 2018315034A1 AU 2018315034 A AU2018315034 A AU 2018315034A AU 2018315034 A AU2018315034 A AU 2018315034A AU 2018315034 A1 AU2018315034 A1 AU 2018315034A1
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- aminomethyl
- ethyl
- benzylcarbamoyl
- ethylcarbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- UCIXIQRCAGGOJY-AJQTZOPKSA-N CCOc1ccc(C[C@H](C(N[C@@H](Cc2ccccc2)C(NCc2ccc(CN)cc2)=O)=O)NC(c2ccccc2)=O)cc1 Chemical compound CCOc1ccc(C[C@H](C(N[C@@H](Cc2ccccc2)C(NCc2ccc(CN)cc2)=O)=O)NC(c2ccccc2)=O)cc1 UCIXIQRCAGGOJY-AJQTZOPKSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762544346P | 2017-08-11 | 2017-08-11 | |
| US62/544,346 | 2017-08-11 | ||
| GB1713660.7 | 2017-08-25 | ||
| GBGB1713660.7A GB201713660D0 (en) | 2017-08-25 | 2017-08-25 | Pharmaceutical compositions |
| PCT/GB2018/052292 WO2019030540A1 (en) | 2017-08-11 | 2018-08-13 | PHARMACEUTICAL COMPOSITIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018315034A1 true AU2018315034A1 (en) | 2020-02-27 |
Family
ID=60037096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018315034A Abandoned AU2018315034A1 (en) | 2017-08-11 | 2018-08-13 | Pharmaceutical compositions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200261383A1 (enExample) |
| EP (1) | EP3664780A1 (enExample) |
| JP (1) | JP2020530475A (enExample) |
| KR (1) | KR20200038987A (enExample) |
| CN (1) | CN111032018A (enExample) |
| AU (1) | AU2018315034A1 (enExample) |
| BR (1) | BR112020002325A2 (enExample) |
| CA (1) | CA3071772A1 (enExample) |
| GB (1) | GB201713660D0 (enExample) |
| MA (1) | MA49837A (enExample) |
| SG (1) | SG11202001179YA (enExample) |
| TW (1) | TW201919600A (enExample) |
| WO (1) | WO2019030540A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
| GB2591730A (en) * | 2019-12-09 | 2021-08-11 | Kalvista Pharmaceuticals Ltd | New polymorphs |
| GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| GB2494851A (en) * | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| AU2013265255B2 (en) * | 2012-05-25 | 2018-03-29 | Novartis Ag | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
| GB2510407A (en) * | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
-
2017
- 2017-08-25 GB GBGB1713660.7A patent/GB201713660D0/en not_active Ceased
-
2018
- 2018-08-13 JP JP2020507672A patent/JP2020530475A/ja active Pending
- 2018-08-13 BR BR112020002325-6A patent/BR112020002325A2/pt not_active IP Right Cessation
- 2018-08-13 MA MA049837A patent/MA49837A/fr unknown
- 2018-08-13 US US16/637,953 patent/US20200261383A1/en not_active Abandoned
- 2018-08-13 KR KR1020207007099A patent/KR20200038987A/ko not_active Ceased
- 2018-08-13 TW TW107128107A patent/TW201919600A/zh unknown
- 2018-08-13 CA CA3071772A patent/CA3071772A1/en active Pending
- 2018-08-13 EP EP18758700.1A patent/EP3664780A1/en not_active Withdrawn
- 2018-08-13 SG SG11202001179YA patent/SG11202001179YA/en unknown
- 2018-08-13 WO PCT/GB2018/052292 patent/WO2019030540A1/en not_active Ceased
- 2018-08-13 CN CN201880052445.0A patent/CN111032018A/zh active Pending
- 2018-08-13 AU AU2018315034A patent/AU2018315034A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020002325A2 (pt) | 2020-09-01 |
| CN111032018A (zh) | 2020-04-17 |
| JP2020530475A (ja) | 2020-10-22 |
| KR20200038987A (ko) | 2020-04-14 |
| GB201713660D0 (en) | 2017-10-11 |
| TW201919600A (zh) | 2019-06-01 |
| EP3664780A1 (en) | 2020-06-17 |
| MA49837A (fr) | 2020-06-17 |
| WO2019030540A1 (en) | 2019-02-14 |
| CA3071772A1 (en) | 2019-02-14 |
| US20200261383A1 (en) | 2020-08-20 |
| SG11202001179YA (en) | 2020-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10478409B2 (en) | Pharmaceutical compositions | |
| US12491183B2 (en) | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | |
| US20200261383A1 (en) | Pharmaceutical compositions | |
| US20220401390A1 (en) | Treatments of diabetic macular edema and impaired visual acuity | |
| JP2017505350A (ja) | 硫黄含有部分を含む糖誘導体ならびにその作製方法およびｍｐｓ ｉｉｉｃの処置のためのその使用方法 | |
| UA125537C2 (uk) | Фармацевтична композиція інгібітора плазмового калікреїну, способи її отримання (варіанти) і застосування | |
| JP2019163227A (ja) | 医薬組成物 | |
| KR20240159823A (ko) | 비감염성 염증성 질환의 치료를 위한 안과 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |